<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02803307</url>
  </required_header>
  <id_info>
    <org_study_id>TLC599A1001</org_study_id>
    <nct_id>NCT02803307</nct_id>
  </id_info>
  <brief_title>Single-Dose Administration Trial of TLC599 in Osteoarthritis of the Knee</brief_title>
  <official_title>A Randomized, Open-label, Parallel, Phase I/II Single-Dose Administration Trial of TLC599 in Subjects With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiwan Liposome Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiwan Liposome Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multi-site, randomized, open-label, parallel, and single-dose administration
      study to investigate the safety and efficacy of TLC599 in subjects with osteoarthritis of the
      knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol No: TLC599A1001

      Name of Finished Product: TLC599

      Title of Study:

      A Randomized, Open-label, Parallel, Phase I/II Single-Dose Administration trial of TLC599 in
      Subjects with Osteoarthritis (OA) of the Knee

      Methodology This trial is a multi-site, randomized, open-label, parallel, and single-dose
      administration study to investigate the safety and efficacy of TLC599 in subjects with
      osteoarthritis of the knee.

      Study duration:

      The trial will last 14 weeks including a 14-day screening period and a 12-week follow-up
      period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety parameters</measure>
    <time_frame>up to 12 weeks after dosing</time_frame>
    <description>Safety parameters will be assessed as measured by adverse events (AEs), changes in physical examinations, vital signs, and clinical laboratory results</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score (VAS)</measure>
    <time_frame>Questionnaire will be collected at baseline, Week 1, Week 4, Week 8, Week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC questionnaire</measure>
    <time_frame>Questionnaire will be collected at baseline, Week 1, Week 4, Week 8, Week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGART questionnaire</measure>
    <time_frame>Questionnaire will be collected at Week 1, Week 4, Week 8, Week 12.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>6 mg TLC599</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg DSP with 50 μmol PL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 mg TLC599</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 mg DSP with 100 μmol PL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TLC599</intervention_name>
    <description>Single dose via intra-articular injection</description>
    <arm_group_label>6 mg TLC599</arm_group_label>
    <arm_group_label>12 mg TLC599</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects, at least 20 years of age

          2. Documented diagnosis of OA of the knee for at least 6 months

          3. At least a grade 2 severity based on the Kellgren and Lawrence Grading Scale

          4. VAS score of ≥ 4 at baseline

        Exclusion Criteria:

          1. Subjects who received systemic corticosteroids for the last 30 days prior to baseline

          2. Subjects who received non-steroidal anti-inflammatory drug (NSAID), analgesics, or
             rehabilitations therapy within 7 days prior to baseline

          3. History of rheumatoid arthritis or other autoimmune disease

          4. Clinical signs and symptoms of acute infection or infection related inflammation in
             the other knee before dosing

          5. History of infective arthritis, suspected or concurrent infection, or suspected or
             confirmed crystal diseases (gout or pseudogout) of the study knee

          6. Concurrent systemic active or uncontrolled infectious disease

          7. A history of treated malignancy which is disease free for ≤ 5 years. (The malignancy
             does not include non-basal-cell carcinoma of skin or carcinoma-insitu of the uterine
             cervix)

          8. History of acquired or congenital immunodeficiency diseases

          9. Platelet count &lt; 80,000/μl, or blood coagulation disorders, including subjects with
             hemophilia, decompensated liver cirrhosis or uremia

         10. Stroke or myocardial infarction within 3 months prior to the screening visit

         11. Use of intra-articular corticosteroid, hyaluronic acid, or other intra-articular
             injection in the study knee joint within 3 months prior to the screening visit

         12. Unstable study knee joint, including anterior cruciate ligament, any surgery to the
             study knee within the 12 months prior to the screening visit, and any prior
             arthroscopic or open surgery of the study knee or any planned/anticipated surgery
             during the study period

         13. Any skin lesion/breakdown at the anticipated injection site or any condition that
             impairs penetration of the study knee joint space

         14. Female subjects who are pregnant, nursing, planning pregnancy, or who are of
             childbearing potential and not using reliable means of contraception 15.Known allergy
             or hypersensitivity to the study drug or its components
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MacKay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>December 16, 2016</last_update_submitted>
  <last_update_submitted_qc>December 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis of the knee</keyword>
  <keyword>TLC599</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>DSP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

